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Abstract
Plasminogen activator inhibitor type-1 (PAI-1) is a member of the serine protease inhibitor
(serpin) family. PAI-1 is involved in the regulation of fibrinolysis, which is the breakdown of
blood clots. PAI-1 inhibits serine proteases tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA), which are key factors in fibrinolysis. Excess levels
of PAI-1 have also been shown to increase the risk of diabetes, stroke, and atherosclerosis, as
well as tumor development. Previous attempts at synthesizing a practical drug for the regulation
of PAI-1 have not been successful; therefore, it has been the purpose of this study to further
advance progress in this area. Working from a lead molecule derived from a high-throughput
library screen, different derivatives were synthesized and tested for anti-PAI-1 activity. By
studying the relationships between different aromatic substitutions, our goal was to discover a
connection between these substitutions and more potent inhibition of PAI-1. This study discusses
the synthesis and impact of the different derivatives of those small molecules on PAI-1
inhibition.
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Chapter I
I-1: Plasminogen Activator Inhibitor-1: Interactions and Diseases
Plasminogen activator inhibitor-1 (PAI-1) is a protein present in all mammals, including
humans. PAI-1 is present in low amounts in the body, but even in such small concentrations, it
has a large impact on human health. PAI-1 has various roles in the body, but the primary one is
to regulate fibrinolysis. Fibrinolysis occurs via the conversion of plasminogen, an inactive
protein, into the enzyme plasmin, which then degrades fibrin clots into products able to be used
by the body in other functions. When PAI-1 binds with tissue-type plasminogen activator (tPA)
and urokinase-type plasminogen activator (uPA), it inhibits the conversion of plasminogen (a
zymogen) into active plasmin, thus regulating the cycle. Therefore, it is understood that an
excess of PAI-1 can lead to hypofibrinolysis: an increase in the level of blood clots.1-3 This has
led to a number of studies that have connected PAI-1 to various blood related diseases such as
thromboembolism, coronary artery disease, sepsis, myocardial infarction, as well as cancer,
atherosclerosis, and type 2 diabetes. 1-3
This is immediately concerning because it shows that PAI-1 is capable of holding
multiple different pathological roles, based on its connection to each disease. When an excess of
PAI-1 is present and hypofibrinolysis occurs, it is thought that there is a parallel increase in the
pathogenesis of atherosclerosis by exposing arteries to chronic thrombosis.3 With the
acceleration of angiogenesis brought on by PAI-1, cancer is able to progress.4-10 PAI-1 has also
been seen to have a relationship with increased levels of amyloid beta in the brain. Amyloid beta
has been known to increase amyloid plaques, thought to cause Alzheimer’s disease.11 Studies
have shown that removing the PAI-1 gene can lead to increased levels of plasmin and tPA, and
decreased levels of amyloid beta in the brain.12
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As previously stated, PAI-1 has been linked to various blood diseases; specifically, in
high concentrations PAI-1 was found to be linked to coronary artery disease as well as
atherosclerosis and myocardial infarction. With PAI-1 in abundance, the balance of fibrin to
fibrin degradation products is severely skewed. This causes plaque buildup and poor regulation
in the arteries of the heart, which in turn can cause hardening of these blood vessels and leads to
more disastrous results, such as heart failure.13,14
In a study where mice were engineered to produce no PAI-1, many of these diseases were
studied. It was found that prognosis of atherosclerosis, thrombosis, and diabetes-induced
nephrosis was noticeably improved. This not only showed that PAI-1 is a factor in these
diseases, but also that reducing PAI-1’s levels may aid in preventing them significantly.15-19 A
similar study conducted with PAI-1 deficiency was shown to prevent obesity as well as a
development of resistance to insulin.3 Other studies have suggested that a deficiency of PAI-1
can aid in the prevention of excess fibrin accumulation and bleomycin-induced fibrosis in the
lungs.20 In contrast, abnormally low levels of PAI-1 also have their drawbacks. PAI-1 deficiency
has been found to be associated with spontaneously developed age-dependent cardiac-selective
fibrosis.21
There exist a few therapies that can aid in some of these diseases; however, many of
these therapies (ACE inhibitors, insulin-sensitizing agents, and hormone replacements) have
been found to indirectly boost fibrinolysis, making them not viable for long term use.22
Therefore, it has been deemed extremely beneficial, considering PAI-1’s vast pathologically
active network, to find regulatory agents specific for PAI-1. Considering it has been a high value
drug target, many attempts have been made to find inhibitors of PAI-1.
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I-2: PAI-1 Structure
PAI-1 is a member of the serine protease inhibitor superfamily. While also known as
endothelial PAI-1 or serpin E1, it is encoded by the serpine1 gene.23 It is primarily synthesized by
tissues of the liver, vascular and adipose; however, it is also stored and secreted by varying
methods.24,25 In humans, PAI-1 is located at chromosome 7q21.30q22, spans about 12,200 base
pairs and is composed of nine exons and eight introns.26,27 It is a single chain glycoprotein
composed of 379 amino acid residues while its secondary structure is composed of 3 β-sheets, 8
or 9 α-helices and a very important reactive center loop (RCL).28,29 A structure of PAI-1 is
shown in Figure 1, but it is also important to know there are other forms of PAI that contribute
to its mechanisms and activity. Most notably, PAI-1 has forms known as active, the Michaelis
complex, covalent and cleaved.

Figure 1. Structure of plasminogen activator inhibitor-130
Shown in Figure 1 is the active form of PAI-1. During this stage the RCL (seen above in
red) is exposed and available for bonding to tissue-type and urokinase-type plasminogen
activators (tPA & uPA). When this occurs, PAI-1 enters a non-covalent Michaelis complex
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(Figure 2).31,32 This acts as an intermediate stage where one of two different pathways may
occur, leading to either the cleaved or latent forms of PAI-1. The RCL undergoes proteolysis and
its amino-terminal end will begin to flip 180 degrees and insert into a second location near the
bottom of the molecule. During this time, if the protease, either tPA or uPA, is able to complete
its catalytic cycle before insertion of the RCL, PAI-1 will take on its inactive cleaved form, while
regenerating the active form of the protease. However, if the protease is not capable of
completing its cycle, it will become trapped in the cleaved form of PAI-1 and become inactive.32

Figure 2. Pathway and forms of PAI-130
While these are the typical pathways there also exist some instances that further
complicate PAI-1’s mode of action. It is possible that PAI-1 will spontaneously convert from its
active form into its latent form at a half-life of approximately 1 to 2 hours. This prevents any
interactions with active proteases and is reported to occur via conformational changes that allow
certain strands of the molecule to slide in and out of place to allow the RCL insertion into a β4

sheet.28,33-39 It is also possible for PAI-1 to be affected by its environment. In the presence of
vitronectin, a glycoprotein found in the extracellular matrix of humans that promotes cell
adhesion and motility, PAI-1 can undergo a conformational change that affects the conformation
of the RCL.40 As seen in Figure 3, PAI-1 can bind with vitronectin specifically via the Nterminal somatomedin-B domain on vitronectin; this stabilizes PAI-1 in its active form,
rendering the RCL unavailable to uPA.34,41

Figure 3. PAI-1 interactions with vitronectin. (a) RCL (b) Vitronectin binding location.30
The interactions of PAI-1 with vitronectin have been found to be able to exceed a 1:1
stoichiometric ratio, which correlates with increased binding of the PAI-1:vitronectin complex to
cells.42 The PAI-1:vitronectin complex is found to be twice as stable as free PAI-1, lengthening
PAI-1’s half-life to upwards of 24 hours.39 However, the primary concern with vitronectin is that
when it binds with PAI-1, it causes a conformational change to the binding site on PAI-1. While
PAI-1 is bound to vitronectin, oligomers of vitronectin begin to form. During this stage tPA can
bind to PAI-1, although this process is strained, and force vitronectin to dissociate from PAI-1.
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When this occurs it is possible for the oligomers of vitronectin to cleave into monomers, further
negatively affecting the cycle involving PAI-1 and its proteases.42

I-3: Previous PAI-1 Inhibitors
Since the discovery of PAI-1 there have been many attempts to develop inhibitors for it.
Monoclonal antibodies (MA) were found to be one of the first direct inhibitors of PAI-1 activity.
Initial MAs were found to act upon PAI-1 in several ways: impeding formation of the Michaelis
complex that PAI-1 forms when binding with tPA/uPA, inducing behavior that cleaves PAI-1
thereby rendering it inactive, and promoting conversion to the latent form of PAI-1 at an
increased rate.33,37,43-46 While these MAs appeared to be strong candidates for the inhibition of
PAI-1, they proved to fall short in bioavailability as they were quickly degraded via enzymes
when taken orally, therefore requiring intravenous injections.
Related studies also looked into the effect of peptides on PAI-1 activity as it was found
that certain sequences could inhibit PAI-1 function. The peptides were able to modify the
conformation of active PAI-1 by acting upon its reactive site loop. For example, a 14 chain
amino acid peptide P14-P1 was shown to hasten the conversion of PAI-1 to its latent form.47
Another peptide was remarkably found to inhibit the binding of PAI-1 to vitronectin, which
would also accelerate conversion to the latent form, largely reducing activity.48 To much
disappointment, however, it was concluded that peptides proved too unstable to be administered
orally, similarly to the monoclonal antibodies. In addition, they exhibited great difficulty in
crossing the blood-brain barrier, making them problematic in treating neurological disorders.
The need for a more specific and bioavailable approach lead to the development of small
molecule inhibitors of PAI-1. There were a few attempts using previously discovered drugs or
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molecules to combat PAI-1. Molecules that were discovered to possess some inhibitory effects
were fibrates, herbal medicines, and butadiene derivatives. One of these fibrates, gemfibrozil,
developed by Fujii et al. was originally shown to help lower lipid levels.49 It also was shown to
aid in decreasing levels of PAI-1 in human hepatoma cells.49 However, other fibrates were
actually found to increase PAI-1 levels in humans, and further, some fibrates were shown to hold
no effect on PAI-1.49 Studies were then performed comparing different fibrates, and it was found
that overall effectiveness greatly depended on type and concentration; however, after further
studies, it was hypothesized that PAI-1 secretion could vary among different types of cells
making it difficult to control, therefore requiring a better understanding of PAI-1 in order to
develop new drugs for it specifically.49
It was then concluded that designing small orally effective molecules designed with PAI1 inhibition in mind would be the most reasonable pathway. The first small molecule inhibitors
of PAI-1, synthesized by Xenova Limited, were diketopiperazines (DKP) derivatives XR330 (I1) and XR334 (I-2). Isolated from a species of Streptomyces, these were capable of inhibiting
PAI-1’s interaction with tPA in vitro with an IC50 of 51 μM.

These molecules had limited solubility and were found to enhance fibrinolysis.50 Subsequent
analogs XR1853, XR5082, XR5118, and XR11211 were developed which also inhibited PAI-1
activity with IC50 values from 3.5-80 μM. These derivatives worked by encouraging the
formation of the latent form of PAI-1, or by inhibiting the binding of PAI-1 to tPA/uPA via
7

structural changes to PAI-1. Of these compounds, XR5118 (I-3) was selected for further studies
in vivo. XR5118 showed increased inhibition of PAI-1 and was the most selective and even
enhanced fibrinolysis while it increased tPA activity in the plasma, indicating a possible
treatment for thrombotic disease.51 XR11211 (I-4) was also studied further as it was also shown
to be effective against PAI-1 with an IC50 of 0.20 μM. However, it suffered from poor
physiochemical properties, and though there were attempts to improve it, development costs and
likelihood of success seemed not worth the effort. These diketopiperazines all seemed to suffer
the same fate as XR11211, as they had poor physiochemical properties and were therefore set
aside for a new attempt at counteracting PAI-1.51-53

One of the most analyzed small molecule inhibitors has been tiplaxtinin (I-5). With an in
vitro IC50 value of 2.7 μM, experimentally shown to contain in vivo selective activity against
PAI-1 in rats, as well as admirable bioselectivity and low toxicity, it appeared to be the front
runner in small molecule inhibitors.54 Despite all of this, however, it was found that tiplaxtinin in
the presence of vitronectin lost nearly all of its ability to inhibit PAI-1. This suggests that the
binding site for both tiplaxtinin and vitronectin overlap.55,56 This prompted further research into
how tiplaxtinin’s mechanism of action proceeds. Utilizing surface plasmon resonance (SPR)
analysis it was discovered that tiplaxtinin will only bind to free PAI-1 and that once PAI-1 is
bound to either vitronectin or becomes latent, there was no observed binding of tiplaxtinin to
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PAI-1.56 When it is able to bind, it does so reversibly and with an IC50 of 9 to 12 μM. During this
binding there is anti-proteolytic activity against uPA and tPA.
Wyeth researchers reported a number of PAI-1 inhibitors as well, of which the leading
molecule was WAY-140312 (I-6). WAY-140312 was found to inhibit PAI-1 with an IC50 value
of 11.7 μM, yet it also reduced thrombosis after oral administration in an in vivo vascular injury
study. However, its bioavailability was only 29% and its half-life was extremely short.57 A later
in vitro study in rat and human plasma found that WAY-140312 lost its activity against PAI-1
due to the presence of vitronectin, much like tiplaxtinin did.55,58 In another study WAY-140312
and tiplaxtinin were tested side by side against a molecule developed by Rupin and co-workers,
S35225 (I-7), a benzothiophene derivative.58 In the presence of vitronectin in rat in vitro and in
vivo models, it was discovered that only S35225 had activity against PAI-1. While it was
effective intravenously in a dose dependent manner, its half-life was not beneficial for long term
use, as it could not be orally administered.58
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A study performed by Bjorquist et al. attempted to look at flufenamic acid derivatives
and found that AR-H029953XX (I-8) inhibits PAI-1 with an IC50 of 12 μM.59 After a structureactivity relationship analysis, it was concluded that an acidic group as well as an aromatic
structure was important in activity against PAI-1.60 Reinforcing this, the Rupin study analyzed
benzothiophene, benzofuran, and indole-based derivatives and reported findings that also pointed
to the importance of an acid functional group and aromatic rings in the structures of PAI-1
inhibitors.58 The apparent downside was that the derivatives also exhibited poor solubility and
bioavailability and, therefore, were not viable options to inhibit PAI-1 as a drug.
In the same vein, Wyeth later reported an oxadiazolidinedione inhibitor (I-9) against PAI1 with an IC50 of 0.39 μM and further expanded their research to synthesize PAI-749 (I-10).52,60
PAI-749 was unique in that it acted on PAI-1 with a dual action mechanism. PAI-749 could bind
to PAI-1 and block the tPA active site, thereby preventing the SDS-stable tPA/PAI-1 complex
formation. It could also bind to PAI-1 in such a way that it would promote the plasmin-mediated
proteolytic degradation of PAI-1. PAI-749 was found to have an IC50 value for tPA inhibition of
0.157 μM and an IC50 value for uPA inhibition of 0.087 μM. PAI-749 was even found to be
effective in the presence of vitronectin and appeared to bind competitively with it.61 Nonetheless
a study performed by Lucking et al. concluded that PAI-749 could in fact not inhibit thrombus
formation or increase fibrinolysis in vitro or ex vivo while tPA was present and, therefore,
alongside of its poor pharmacokinetic properties, was not a viable PAI-1 inhibitor for human
systems.62

10

Wyeth subsequently developed PAZ-417 (structure unrevealed), a molecule that was
found to reduce Aβ levels in plasma and in the brain. It had an IC50 value against PAI-1 of 0.655
μM and although it seemed to show promise, nothing was published on its clinical results.57
With developing technology, another molecule was discovered through high throughput
screening. ZK4044 (I-11) was found to be effective against PAI-1 with an IC50 value of 0.644
μM. ZK4044 selectively binds to PAI-1 over other serpins and was found to directly inhibit
binding of PAI-1 to tPA and uPA. Interestingly, ZK4044 was also discovered to prevent
conversion of PAI-1 from active to latent form. However, due to its hydrophobic menthol-based
structure, it requires optimization before further pharmacological use.24

In 2007 our research group began a collaborative effort with that of Professor Daniel
Lawrence of the University of Michigan Medical School in order to further advance the
discovery and development of novel small molecule inhibitors of PAI-1. With the aid of a high
throughput screen of the MicroSource SPECTRUM compound library, Lawrence and his group
11

were able to identify a total of 19 varied compounds that displayed activity against PAI-1.
Interestingly, three of these molecules contained galloyl moieties (3,4,5-trihydroxybenzoates).56
ECGC (I-12) and EGCDG (I-13), each containing three gallate groups, were found to
have strong PAI-1 inhibitory activity. However the necessary purification and synthesis methods
were deemed too expensive and laborious.

The third, tannic acid (I-14), is a naturally occurring polyphenolic compound whose structure
suggests potential PAI-1 activity due to its large number of gallate groups. Although it is a potent
PAI-1 inhibitor with an IC50 value of 7 nM, it would not make a very successful drug due to its
high molecular weight and tendency to form aggregates at micromolar concentrations. Therefore,
a second generation of derivatives were synthesized that exhibited enhanced potency of PAI-1
activity by 10-1000 fold over previously reported inhibitors (Figure 4).56 These new compounds
displayed better PAI-1 activity than tiplaxtinin and were able to inhibit the Michaelis-like
complex that forms between PAI-1 and tPA/uPA. They were also importantly shown to inhibit
victonectin-bound PAI-1. They were capable of reversibly binding to PAI-1 with high affinity,
indicating their IC50 values were not time dependent.

12

Figure 4. Second generation synthesized compounds
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Figure 4 (continued). Second generation synthesized compounds
The structures of compounds CDE-004 (I-15) and CDE-066 (I-22) retained many of
tannic acid’s gallate groups, and their anti-PAI-1 activity in the low nM range spurred further
synthesis of molecules with fewer gallate groups to test the effect on activity against PAI-1. A
concurrent goal was to investigate the linking unit’s role in the molecule’s activity. CDE-008 (I18), CDE-044 (I-16) and CDE-071 (I-17) were synthesized with these factors in mind. However,
it was expected that the ester linkages would be susceptible to hydrolysis by esterases as well as
by the acidic environment of the stomach. This made in vivo testing very limited and ruled out
oral administration.56 In addition, it was found that this class of compounds did not typically
retain activity against PAI-1 in ex vivo experiments containing plasma proteins, most likely due
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to their ester linkages. On the other hand, those with more galloyl groups seemed to perform
better against PAI-1 in plasma.
In an attempt to overcome this issue, the ester linkages were replaced with more stable
bis-arylsulfonamides and aryl sulfonamide groups in a series of compounds (Table 1). It was
found that molecules that contained two sulfonyl groups were most effective against PAI-1,63
that 3,4-dihydroxy substitution gave the lowest IC50 values, and that some non-symmetric
inhibitors also proved effective (CDE-187 and 198).63 While these molecules have shown
promise and were further investigated by our research group, one of their major setbacks was
loss of activity in assays containing plasma.30
Table 1. Sulfonamide and sulfonimide based inhibitors
CDE Code
Structure

IC50 Value (μM)

CDE-032

9.45

CDE-119

6134

CDE-132

1384

CDE-135

104

CDE-140

318

15

CDE-165

0.35

CDE-183

0.18

CDE-187

0.91

CDE-198

0.051

In order to find another lead compound, a second high throughput library screen was
performed on a much larger set of molecules maintained by the Center for Chemical Genomics
(CCG) at the University of Michigan. This screen discovered two main molecules with anti-PAI1 activity. Of these, I-24, was chosen for further studies due to its low molecular weight, low
micromolar IC50 value of 36 μM, and suitability as a framework for synthesizing many
derivatives. I-24 lacks any galloyl groups in exchange for a single benzene ring with a para
16

substituted chlorine, drawing electron density out of the ring. It also includes a highly active
hydrazide on its opposite end. We decided that our research group would undertake the challenge
of synthesizing a host of analogs to I-24 in order to better understand the structure activity
relationships between various moieties in the compound and PAI-1 inhibition.
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Chapter II
II-1: Novel Small Molecule Inhibitors of PAI-1

The main goal of my work was to improve the lead molecule’s IC50 value, as well as to
analyze structure activity relationships of various structural features of this PAI-1 inhibitor. I
pursued these goals by synthesizing various analogs of I-24 with variations at three locations: I
substituted different groups on the aromatic ring, extended the oxalyl core chain length, and
exchanged the hydrazide group on the end of the lead molecule with other moieties (Figure 5).
Oxalyl Core

Aromatic Substituent
Variations

Hydrazide

Figure 5. Locations of analogue syntheses
II-2: Aromatic Substituent Variations
My first objective was to vary substituents on the aromatic ring to study their effect on
PAI-1 inhibitory activity. Scheme 1 details the general procedure for synthesizing these
analogues. Substituted benzylamines were placed in a solution of pyridine and methylene
chloride. To this, ethyl oxalyl chloride was added to form an ester intermediate. This ester was
then dissolved in ethanol and treated with hydrazine hydrate to provide the final product to be
analyzed for activity versus PAI-1.
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Scheme 1. Synthesis of lead molecule analogs from benzene ring substitutions. Reagents
and conditions: a. ethyl oxalyl chloride, pyridine, CH2Cl2, 0 ºC to r.t.; b.
hydrazine hydrate, ethanol, r.t.
Following synthesis and verification of product via 1H NMR and 13C NMR, all products
were tested in Dr. Lawrence’s lab for inhibitory activity versus PAI-1. Molecules were tested
under two conditions: a simple pH 7.4 buffer with PAI-1 and uPA, and with the addition of 1.5%
bovine serum albumin (BSA) to the pH 7.4 buffer. The BSA adds proteins that allow the assay to
more closely mimic the physiological conditions of a whole organism. The molecules that were
synthesized and their inhibitory assay results are shown in Table 2.
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Table 2: Oxalyl core benzene ring substituent variations.

a

R6

IC50
(μM)
pH 7.4

IC50
(μM)
1.5%
BSA

H

H

117

54

OCHF2

H

H

>3000

324

H

H

H

OCHF2

>3000

>3000

F

CF3

H

H

H

387

157

CDE-492

F

CH3

H

H

F

3188

1274

CDE-493

F

F

F

H

H

809

267

CDE-494

Cl

F

H

H

F

>3000

>3000

CDE-495

H

CF3

F

H

H

247

99.6

CDE-496

H

H

iPr

H

H

976

205

CDE-497

H

H

N(CH3)2

H

H

>3000

469

CDE-498

H

H

CH2CH3

H

H

2679

134

CDE-499

H

CH3

F

H

H

268

90.7

CDE-268a

H

OCF3

H

H

H

131

109

Compound
Code
Category A

R2

R3

R4

R5

Lead (I-24)

H

H

Cl

CDE-486

H

H

CDE-487

H

CDE-488

Compound synthesized by Naga Guntaka. Substituent locations shown in Scheme 1.
Analysis of the data acquired for the analogues I synthesized suggests that an

electronegative group in the para (R4) position on the ring leads to lower IC50 values. For
example, when comparing CDE-486, with the substituent in the para position, and CDE-487,
where it is meta, CDE-486 has a significantly lower IC50 in BSA.
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A similar parallel is seen between CDE-492 and CDE-499. The inclusion of a fluorine
atom in the para (R4) position of CDE-499 seems to have drastically improved its inhibition
capability. It should be noted that the fluorine in the second position on the ring has been
removed in CDE-499, which may have some effect in the change of IC50 values, as many
compounds without an electron withdrawing group at that position show a trend of possessing
lower IC50 values.

The data indicates a correlation between lower IC50 values and the presence of
substituents in the para position, as well as a preference for electron withdrawing groups at that
position, as opposed to electron donating groups. CDE-497 was synthesized with an electron
donating tertiary nitrogen at the para position; while measurable inhibition does occur within the
test range, it is noticeably worse than previous molecules that contain electron withdrawing
groups at that position. In the same sense, CDE-496, containing an isopropyl group, which is far
less withdrawing than the groups on some of the other molecules synthesized, is also seen to
have a more effective inhibitory effect than that of CDE-497.
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It is interesting to note that there is a correlation between a substituent on the ortho (R6)
position and a decreased inhibitory effect. CDE-493 and CDE-494 contain similar
electronegative substituents, with the main difference being the position of the third substituent.
CDE-493 contains a para (R4) substituent while CDE-494 has a second ortho (R6) substituent.
This difference results in a significant decrease in inhibitory effect for CDE-494. This is also
seen in the previous comparison of CDE-486 and CDE-487, as well as CDE-492, which has the
third least effective IC50 value.

II-3: Extension of Core Chain Length Analogues
The second portion of my research was to determine the effect of extending the two carbon oxalyl core to the three and four carbon malonyl and succinyl cores, respectively (Figure
6). In these cases only one benzyl amine was used for all syntheses. A trifluoromethoxy group on
the meta (R3) position on the ring was utilized. This was done in an effort to keep the aromatic
ring substitution consistent, as well as benefit from the previous use of this benzyl amine in the
syntheses of similar molecules. In these syntheses, the hydrazide group was modified to match
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other molecules with the original oxalyl core, where the molecules I synthesized and their
inhibitory assay results are listed in Table 3 and Table 4; and their original counterparts are
displayed in Table 5.

Figure 6. Malonyl (a) and Succinyl (b) cores
The intermediate esters leading to CDE compounds 501, 502, 503, 504, 505, 506, 509,
511, 521, 522, 523, and 524 were synthesized in the same manner as previous benzyl amine
analogues. 3-Trifluoromethoxy benzyl amine was added to a solution of methylene chloride and
pyridine. Methyl malonyl chloride or methyl succinyl chloride was added dropwise to provide
the resulting ester. The esters then underwent the appropriate reactions in order to afford the final
compounds. CDE-502 and 511 were treated with hydrazine hydrate; CDE-503 and 521 were
subjected to aqueous base; CDE-504, 505, 522, and 523 were reacted with a beta amide ester salt
under standard peptide-coupling conditions; CDE-506 and 524 were treated with ammonia in
methanol (7 N) (Scheme 2).
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Scheme 2. Syntheses of malonyl & succinyl compounds with varying end moieties.
Reagent and conditions. (a): methyl malonyl chloride, pyridine, CH2Cl2, 0 ºC
to rt. (b): methyl succinyl chloride, pyridine, CH2Cl2, 0 ºC to rt. (c): CDE-502
and CDE-511: hydrazine hydrate, EtOH; 503, 521: aq. NaOH (5M), EtOH;
CDE-504, 522: 2-amino-1-pyrrolidin-1-yl-ethanone hydrochloride, HOBt ·
H2O, DMF, N-methylmorpholine, H2Cl2, EDC · HCl; CDE-505, 523: 2amino-1-morpholino-1-ethanone hydrochloride, HOBt · H2O, DMF, Nmethylmorpholine, H2Cl2, EDC · HCl; CDE-506 and CDE-524: ammonia in
methanol, EtOH.
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Table 3. Malonyl-based compounds.

OCH3

IC50 (μM)
pH 7.4
>3000

IC50 (μM)
1.5% BSA
>3000

CDE-511

NHNH2

>3000

>3000

CDE-521

OH

721

>3000

CDE-522

>3000

>3000

CDE-523

>3000

>3000

139

>3000

IC50 (μM)
pH 7.4
>3000

IC50 (μM)
1.5% BSA
1383

Compound Code

X

CDE-509

CDE-524

NH2

Table 4. Succinyl-based Compounds.
Compound Code
X
Category A
CDE-501
OCH3
CDE-502

NHNH2

2017

801

CDE-503

OH

>3000

>3000

CDE-504

948

836

CDE-505

4273

2402

921

3298

CDE-506

NH2

28

Table 5. Previously synthesized inhibitors.
Compound Code

X

IC50 (μM)
pH 7.4

IC50 (μM)
1.5% BSA

CDE-471b

NH2

421

156

CDE-507a

>3000

>3000

CDE-489a

>3000

2374

Synthesized by: aJen Corker, bRaKeenja Fluellen.
The results seen in Table 6 give an interesting insight into the effect of core chain length
on the results of the bio assays for this set of molecules. It was hypothesized that there would be
a correlation between core length and activity, with one length consistently producing better
results than the others. However, that is not the case here. The only consistent result is that
molecules with the malonyl core have no activity when in a protein system. This could be due to
the atypically acidic C-H bonds on the carbon chain being more susceptible to deprotonation
and, therefore, the possible creation of unfavorable interactions with other proteins than those of
the succinyl chain protons (the oxalyl chain contains no acidic protons between carbonyls). It is
particularly intriguing that even the hydrazide extension on the malonyl core has no activity
when every other assay has shown the hydrazide group to produce a significant increase in
inhibitory effect.
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Table 6. Direct comparison of varying core length inhibitors.
Oxalyl IC50 (μM)
Malonyl IC50 (μM)
X

pH 7.4

OCH3

pH 7.4

-

1.5%
BSA
-

NHNH2

131

OH

NH2

Succinyl IC50 (μM)
pH 7.4

>3000

1.5%
BSA
>3000

>3000

1.5%
BSA
1383

109

>3000

>3000

2017

801

-

-

721

>3000

>3000

>3000

>3000

>3000

>3000

>3000

948

836

>3000

2374

>3000

>3000

4273

2402

421

156

139

>3000

921

3298

The oxalyl-based inhibitors exhibit better activity than either of the malonyl or succinyl
compounds; however, the compound containing the morpholine ring has nearly the same IC50 as
the succinyl compound, offsetting the trend. Future research could explore further extension of
the core in order to assess the inhibitory effect of chain length, as well as other various end
moieties.

II-4: Alpha-Beta Unsaturated Malonyl Derivatives
In an effort to increase our understanding of the relationship of structure to inhibition
activity, our group is synthesizing an increasingly diverse set of molecules. One of the benefits
of extending the core length from our lead molecule to a malonyl core is the ability to utilize the
alpha-carbon at each carbonyl as a reactive center for new reactions. I focused on employing a
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Knoevenagel reaction, which converts the sp3-hybridized carbon at the carbonyl position to an
sp2-hybridized carbon bound to an additional group. In a microwave tube, I added an aldehyde of
choice and piperidine to the previously synthesized malonyl ester (CDE-509). Later syntheses
involved the addition of ethyl alcohol as a solvent. The mixture was then subjected to microwave
irradiation at 100 ºC for 7.5 minutes, followed by an acidic workup (Scheme 3).

Scheme 3. Synthesis of alpha-beta unsaturated malonyl derivatives. Reagents &
conditions: Piperidine (0.25 eq.), various aldehyde (5 eq.). Microwave irradiation at 250W, 100
ºC, 7.5 minutes, no stirring. Later syntheses involved the addition of EtOH as solvent.
The first attempt was made using butyraldehyde (Scheme 4). Preliminary TLC results
suggested contamination by side reactions so the product was purified by column
chromatography. Post column TLC staining revealed persistent contamination. Preliminary 1HNMR indicated a lack of product as well as too many side products to warrant further pursuit.
This first attempt was therefore abandoned and a second aldehyde was tried.

Scheme 4. Synthesis of alpha-beta unsaturated malonyl derivative using butyraldehyde.
Reagents & conditions: Piperidine (0.25 eq.), butyraldehyde (5 eq.) Microwave irradiation at
250W, 100ºC, 7.5 minutes, no stirring.
Nonanal was used in an attempt to drive the reaction forward in a more stereo-selective
manner due to its long aliphatic chain while keeping the chemistry similar (Scheme 5). In the
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same way, the aldehyde was added to a microwave tube with piperidine and the starting malonyl
ester, then placed in the microwave at 100 ºC for 7.5 minutes. Following an acid workup, a
column was run in 1% ethyl acetate:hexanes. 1H-NMR analysis of the resulting separated
compounds was inconclusive, and therefore, further TLC staining was performed. Again, this
revealed multiple, previously unseen “spots”, and therefore, any further attempts at purification
were dismissed.

Scheme 5. Synthesis of alpha-beta unsaturated malonyl derivative using nonanal.
Reagents & conditions: Piperidine (0.25 eq.), nonanal (5 eq.) Microwave irradiation at 250W,
100 ºC, 7.5 minutes, no stirring.
A third attempt at making the desired Knoevenagel reaction proceed correctly
was via the use of veratraldehyde (Scheme 6). This aldehyde was chosen due to its bulky
aromatic group, with hopes that its steric bulk would help drive the reaction towards selectively
producing a single isomer. CDE-512 was obtained after workup and a column run in 40% ethyl
acetate:hexanes. 2D NMR techniques were then utilized to verify that the Z isomer of CDE-512
was the nearly exclusive product (I-25).
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Scheme 6. Synthesis of alpha-beta unsaturated malonyl derivative using veratraldehyde.
Reagents & conditions: Piperidine (0.25 eq.), veratraldehyde (5 eq.) Microwave irradiation at
250W, 100 ºC, 7.5 minutes, no stirring.

1D 1H-NMR, 1D 13C-NMR, COSY, HMQC, and NOESY were used to determine the
stereochemistry of CDE-512. Evidence of the exclusive formation of the Z isomer was provided
mostly by the interactions in the NOESY spectrum of the amide hydrogen solely with its
neighboring benzylic hydrogens (Figure 7). No other spatial interactions were observed, had the
E isomer been present, it would likely have shown an interaction between the amide hydrogen
and the second aromatic ring.
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Figure 7. NOESY data of CDE-512. Red box indicates interaction between amide
hydrogen & benzylic protons. Lack of any other interactions gives evidence of Z isomer.
It may be argued that if CDE-512 were in the Z conformation we would see interactions
between the vinylic hydrogen and the hydrogen on the amine, which was not observed. This may
be due to a lack of specificity in the experiment or these hydrogens being too far away to have
any interactions while in the Z conformation. Molecular modeling suggests that the amide
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hydrogen could be pointed away from the vinylic proton which also may explain the lack of
interaction between the two.
We suspected that CDE-512 would show little activity versus PAI-1 due to its lack of a
hydrazide group. However, we were surprised by an almost complete lack of any activity, even
in very concentrated amounts (3000 µM). Formation of the hydrazide analog was then attempted
using previously-detailed methods (Scheme 7). Hydrazine hydrate was added to a solution of
CDE-512 in ethanol. Through multiple TLC and column runs, it was determined that no desired
hydrazide product was formed and we decided to undertake another method.

Scheme 7. Formation of hydrazide from alpha-beta unsaturated malonyl compound.
Reagents & conditions: CDE-512 (1 eq.), hydrazine hydrate (2 eq.), ethanol, 24 hours, r.t.
I attempted to synthesize the desired product by subjecting the previously synthesized
malonyl hydrazide (CDE-511) in place of the ester (CDE-509) to the Knoevenagel reaction
(Scheme 8). In a microwave tube, the malonyl hydrazide was combined with 0.25 eq of
piperidine, 5 eq of veratraldehyde and 1 mL of EtOH and the reaction mixture was subjected to
the same conditions as before. A number of different species were identified via TLC and a
column was run to isolate the unidentified products. The 1H NMR spectrum was inconclusive as
to the identity of the products, and therefore, we performed a second synthesis in an effort to
obtain the desired products.
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Scheme 8. Alternate synthesis for the formation of hydrazide malonyl compound
using veratraldehyde. Reagents & conditions: CDE-511 (1 eq.), Piperidine (0.25 eq.),
veratraldehyde (5 eq.), ethanol (2 mL). Microwave irradiation at 250W, 100 ºC, 7.5 minutes,
stirring.
In the same manner as before, I added the malonyl hydrazide to a microwave tube with
piperidine, EtOH and butyraldehyde (Scheme 9). I used butyraldehyde again despite the
previous lack of success because it is a much easier molecule to identify via NMR. In particular,
I was looking for the absence of carbonyl alpha protons as well as the presence of a single
vinylic proton, which could be easily masked by veratraldehyde in an impure sample. The
resulting product was triturated with diethyl ether and a white granular solid was obtained. After
drying under vacuum, the sample was subjected to 1H-NMR. We found a near 1:1 ratio of E : Z
isomers; however carbonyl alpha protons were still present near 3.1 ppm and 3.4 ppm. This led
me to the conclusion that I had formed the hydrazone instead (Figure 8).

Scheme 9. Alternate synthesis for the formation of hydrazide malonyl compound
using butyraldehyde. Reagents & conditions: CDE-511 (1 eq.), Piperidine (0.25 eq.),
butyraldehyde (5 eq.), ethanol (2 mL). Microwave irradiation at 250W, 100 ºC, 7.5 minutes,
stirring.
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Figure 8. Hydrazone butyraldehyde product reaction
The same analysis was applied to the previously observed veratraldehyde/hydrazide 1HNMR. Two singlet peaks from protons alpha to the carbonylsin isomers of the undesirable
hydrazone product were identified (Figure 9). As a consequence of these results and due to
additional impurities, the synthesis of this compound was not pursued further.

Figure 9. Hydrazone product of veratraldehyde
However, the butyraldehyde hydrazone isomers were of higher purity, and we could
perform further attempts to obtain the desired hydrazide product. I attempted to add the
veratraldehyde to the originally intended position, hoping that I could reverse the formation of
the hydrazone back to the hydrazide following the successful addition of veratraldehyde to the
compound (Scheme 10). I exposed the hydrazone with the common reagents and veratraldehyde
to microwave irradiation as detailed above.
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Scheme 10. Synthesis of hydrazone with veratraldehyde. Reagents & conditions:
Piperidine (0.25 eq.), veratraldehyde (5 eq.), ethanol (3 mL). Microwave irradiation at 250W,
100 ºC, 7.5 minutes, stirring.
Following an acidic workup, TLC was analyzed and it was found that no reaction had
taken place. At this point I had a near homogenous solid of starting hydrazone and
veratraldehyde, and therefore, decided to try one last reaction with what little materials I had left.
The recovered starting materials from Scheme 10 were dissolved in EtOH and 4 drops of
glacial acetic acid were added. The sample underwent microwave irradiation for 35 minutes,
followed by an acid workup as well as a trituration following preliminary NMR. This reaction
did not proceed and only miniscule amounts of starting material remained. In the future it could
be beneficial to revisit this reaction path. We have observed that the acidic protons in the carbon
chain of the other malonyl-based compounds are likely the cause of instability in protein assays.
Minor alterations at this site could lead to more potent inhibitors as both the terminal alcohol and
amine compounds had moderate inhibition in pH 7.4 buffer. If those compounds could be
stabilized, it would be advantageous to test their inhibitory effects in a protein assay.

II-5: Conclusions
The objective of my research was to synthesize novel small molecules as inhibitors of
plasminogen activator inhibitor-1. I synthesized a series of compounds that can be added to a
small library of analogues based around the lead molecule, I-24. I varied three aspects of the
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structure of these compounds. First I altered the nature and position of substituents to the
benzene ring while keeping the rest of the molecule the same. I found that there is a positive
correlation between inhibitory effect and the presence of an electronegative group at the para
(R4) position. In addition, a substituent at the ortho (R2 or R6) position tends to weaken the
inhibitory effect. The second structural modification was to extend the carbon core of the lead
molecule and the third modification was to remove and substitute the hydrazine end. Results
from these two modifications varied, but it is clear that the three carbon chain malonyl molecules
are significantly less effective than the two carbon oxalyl or four carbon succinyl molecules.
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Experimental Methods & Data

Ethyl 2-((4-(difluoromethoxy)benzyl)amino)-2-oxoacetate (KMU-1-1): To a solution of 4(difluoromethoxy)benzylamine (0.265 mL, 1.83 mmol) and pyridine (0.30 mL, 3.66 mmol) in
2.0 mL of CH2Cl2 stirred in an ice bath, ethylchlorooxoacetate (0.21 mL, 1.92 mmol) was added
dropwise. The reaction was allowed to stir for one hour. The reaction mixture was then diluted
with 30 mL ethyl acetate and washed with 2 × 25 mL of 0.2N HCl, followed by 2 × 25 mL sat.
aqueous NaHCO3. The organic phase was then dried with anhydrous MgSO4, filtered and
concentrated to provide 335.0 mg (67.1%) of the pale yellow solid. 1H-NMR (CDCl3, 400 MHz)
δ 7.52 (bs, 1H), 7.52 (bs, 1H), 7.27 (d, J=8.7 Hz, 2H), 7.05 (d, J=8.7 Hz, 2H), 6.47 (t, J=6.4 Hz,
2H), 4.29 (q, J=7.32 Hz, 2H), 1.34 (t, J=6.88 Hz, 3H).

N-(4-(difluoromethoxy)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-486): A solution of
KMU-1-1 (157.1 mg, 0.549 mmol) and hydrazine hydrate (0.068 mL, 1.098 mmol, ~50% in
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The amorphous solid was
filtered and dried under high vacuum to provide 305.0 mg (quantitative yield) of CDE-486 as an
off-white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.00 (bs, 1H), 9.25 (t, J=5.9 Hz, 1H), 7.17
(dd, J=8.7 Hz, 75.6 Hz, 4H), 7.15 (t, J=74.7 Hz, 1H), 4.50 (bs, 2H), 4.25 (d, J=6.44 Hz, 2H).
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C NMR (DMSO-d6, 100 MHz) δ 160.35, 158.55, 150.36, 136.44, 129.57, 119.26, 116.92 (t,

13

J=256.5 Hz), 40.23; HRMS, DART calcd. for C10H11F2N3O3 [M+H+] 260.08467, found:
260.08401.

Ethyl 2-((2-(difluoromethoxy)benzyl)amino)-2-oxoacetate (KMU-1-3): The procedure for the
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)benzylamine for 2(difluoromethoxy)benzylamine which gave 471.2 mg (94.4%) of KMU-1-3 as a yellow solid. 1H
NMR (CDCl3, 400 MHz) δ 7.80 (m, 5H), 6.58 (t, J=73.7 Hz, 1H), 4.56 (d, J=5.96 Hz, 2H), 4.33
(q, J=7.32 Hz, 2H), 1.37 (t, J=7.32 Hz, 3H).

N-(2-(difluoromethoxy)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-487): A solution of
KMU-1-3 (124.7 mg, 0.456 mmol) and hydrazine hydrate (0.058 mL, 0.912 mmol, ~50% in
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The amorphous solid was
filtered and dried under high vacuum to provide 68.5 mg (58.1%) of CDE-487 as a white solid.
1

H NMR (DMSO-d6, 400 MHz) δ 10.04 (bs, 1H), 9.13 (t, J=6 Hz, 1H), 7.20 (m, 5H), 4.51 (bs,

2H), 4.32 (d, J=6 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 160.54, 158.41, 148.98, 129.96,
129.08, 128.95, 125.81, 118.86, 117.13 (t, J=257.4 Hz), 37.41; HRMS, DART calcd. for
C10H11F2N3O3 [M+H+] 260.08467, found: 260.08301.
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Ethyl 2-((2-fluoro-3-(trifluoromethyl)benzyl)amino)-2-oxoacetate (KMU-1-4): The
procedure for the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)benzylamine for 2-fluoro-3-(trifluoromethyl)benzylamine which gave 487.9 mg (91.0%) of
KMU-1-4 as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.57 (m, 3H), 7.21 (t, J=7.8 Hz, 1H),
4.6 (d, J=6.4 Hz, 2H), 4.34 (q, J=7.4 Hz, 2H), 1.37 (t, J=7.3 Hz, 3H).

N-(2-fluoro-3-(trifluoromethyl)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-488): A solution
of KMU-1-4 (116.4 mg, 0.397 mmol) and hydrazine hydrate (0.049 mL, 0.794 mmol, ~50% in
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The amorphous solid was
filtered and dried under high vacuum to provide 50.3 mg (45.7%) of CDE-488 as a white solid.
1

H NMR (DMSO-d6, 400 MHz) δ 10.06 (bs, 1H), 9.33 (t, J=6.4 Hz, 1H), 7.61 (dt, J=6.9 Hz,

J=22.9 Hz, 2H), 7.34 (t, J=7.8 Hz, 1H), 4.51 (d, J=4.1 Hz, 2H), 4.39 (d, J=6 Hz, 2H). 13C NMR
(DMSO-d6, 100 MHz) δ 160.63, 158.25, 157.20 (d, J=254.6 Hz), 134.97 (d, J=4.8 Hz), 127.9 (d,
J=13.4 Hz), 126.48 (d, J=4.8 Hz), 125.26 (d, J=3.8 Hz), 123.25 (q, J=269.8 Hz), 116.9 (m),
36.19 (d, J=4.8 Hz); HRMS, DART calcd. for C10H9F4N3O2 [M+H+] 280.07090, found:
280.07199.
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Ethyl 2-((2,6-difluoro-3-methylbenzyl)amino)-2-oxoacetate (KMU-1-7): The procedure for
the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 2,6difluoro-3-methylbenzylamine which gave 435.8 mg (92.7%) of KMU-1-7 as an off-white solid.
1

H NMR (CDCl3, 400 MHz) δ 7.31 (bs, 1H), 7.1 (q, J=8.7 Hz, 1H), 6.8 (t, J=8.7 Hz, 1H), 4.6 (d,

J=6 Hz, 2H), 4.32 (q, J=7.3 Hz, 2H), 2.23 (t, J=0.9 Hz, 3H), 1.37 (t, J=6.9 Hz, 3H).

N-(2,6-difluoro-3-methylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-492): A solution of
KMU-1-7 (152.2 mg, 0.592 mmol) and hydrazine hydrate (0.074 mL, 1.184 mmol, ~50% in
H2O) in 6 mL ethanol was stirred for one hour at room temperature. The solid was filtered and
dried under high vacuum to provide 118.5 mg (82.3%) of CDE-492 as a white solid. 1H NMR
(DMSO-d6, 400 MHz) δ 9.99 (bs, 1H), 8.97 (t, J=6 Hz, 1H), 7.2 (q, J=8.2 Hz, 1H), 6.92 (t, J=9
Hz, 1H), 4.47 (bs, 2H), 4.34 (d, J=5.5 Hz, 2H), 2.14 (s, 3H). 13C NMR (DMSO-d6, 100 MHz) δ
160.04, 159.66 (dd, J=8.58 Hz, J=244.1 Hz), 159.57 (dd, J=8.59 Hz, J= 246.0 Hz), 158.39,
131.14 (dd, J=6.7 Hz, J=9.5 Hz), 120.60 (dd, J=3.81 Hz, J=18.11 Hz), 113.58 (t, J=19.1 Hz),
111.20 (dd, J=3.8 Hz, J=21.9 Hz), 31.57, 14.25 (d, J=2.9 Hz); HRMS, DART calcd. for
C10H11F2N3O2 [M+H+] 244.08976, found: 244.08900.

Ethyl 2-oxo-2-((2,3,4-trifluorobenzyl)amino)acetate (KMU-1-12): The procedure for the
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 2,3,443

trifluorobenzylamine which gave 420.6 mg (88.1%) of KMU-1-12 as an off-white solid. 1H
NMR (CDCl3, 400 MHz) δ 7.43 (bs, 1H), 7.10 (m, 1H), 6.93 (ddt, J=6.9 Hz, J=6.9 Hz, J=6.9
Hz, 1H), 4.54 (d, J=6.4 Hz, 2H), 4.34 (q, J=6.8 Hz, 2H), 1.38 (t, J=6.9 Hz, 3H).

2-hydrazinyl-2-oxo-N-(2,3,4-trifluorobenzyl)acetamide (CDE-493): A solution of KMU-1-12
(139.9 mg, 0.538 mmol) and hydrazine hydrate (0.067 mL, 1.071 mmol, ~50% in H2O) in 6 mL
ethanol was stirred for one hour at room temperature with manual breakup of the solid required.
The sturdy solid was filtered and dried under high vacuum to provide 104.2 mg (78.8%) of
CDE-493 as an off-white stiff solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.04 (bs, 1H), 9.28 (t,
J=6 Hz, 1H), 7.24 (m, 1H), 7.11 (m, 1H), 4.51 (bs, 2H), 4.32 (d, J=6 Hz, 2H). 13C NMR
(DMSO-d6, 100 MHz) δ 160.53, 158.25, 149.90 (ddd, J=2.8 Hz, J=9.5 Hz, J=245.0 Hz), 148.96
(ddd, J=2.8 Hz, J=10.5 Hz, J=247.0 Hz), 139.33 (dt, J= 15.3 Hz, J=246.9 Hz), 124.37 (m),
124.10 (dd, J=2.8 Hz, J=12.4 Hz), 112.90 (dd, J=2.8 Hz, J=16.2 Hz), 36.06; HRMS, DART
calcd. for C9H8F3N3O2 [M+H+] 248.06468, found: 248.06300.

Ethyl 2-((2-chloro-3,6-difluorobenzyl)amino)-2-oxoacetate (KMU-1-8): The procedure for
the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 2chloro-3,6-difluorobenzylamine which gave 401.2 mg (79.1%) of KMU-1-8 as an off-white
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solid. 1H NMR (CDCl3, 400 MHz) δ 7.35 (bs, 1H), 7.12 (m, 1H), 7.01 (m, 1H), 4.71 (dd, J=1.4
Hz, J=6.0 Hz, 2H), 4.33 (q, J=7.4 Hz, 2H), 1.37 (t, J=6.9 Hz, 3H).

N-(2-chloro-3,6-difluorobenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-494): A solution of
KMU-1-8 (148.8 mg, 0.536 mmol) and hydrazine hydrate (0.067 mL, 1.072 mmol, ~50% in
H2O) in 4 mL ethanol was stirred for one hour at room temperature. The solid was filtered and
dried under high vacuum to provide 87.2 mg (61.8%) of CDE-494 as a white, granular solid. 1H
NMR (DMSO-d6, 400 MHz) δ 10.01 (bs, 1H), 9.03 (bs, 1H), 7.39 (m, 1H), 7.24 (m, 1H)
4.49 (bs, 2H), 4.42 (d, J=5.5 Hz, 2H). 13C NMR (DMSO-d6, 100 MHz) δ 160.19, 158.26, 157.64
(d, J=244.1 Hz), 154.45 (d, J=240.1 Hz), 125.52 (d, J=19.1 Hz), 121.91 (dd, J=19.1 Hz, J=5.7
Hz), 116.90 (dd, J=23.8 Hz, J=9.5 Hz), 115.62 (dd, J=25.7 Hz, J=8.6 Hz), 35.16; HRMS,
DART calcd. for C9H8ClF2N3O2 [M+H+] 264.03514, found: 264.03601.

Ethyl 2-((4-fluoro-3-(trifluoromethyl)benzyl)amino)-2-oxoacetate (KMU-1-11): The
procedure for the synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)benzylamine for 4-fluoro-3-(trifluoromethyl)benzylamine which gave 462.5 mg (86.2%) of
KMU-1-11 as a yellow solid. 1H NMR (CDCl3, 400 MHz) δ 7.51 (m, 3H), 7.18 (t, J=9.6 Hz,
1H), 4.53 (d, J=6.4 Hz, 2H), 4.36 (q, J=7.3 Hz, 2H), 1.39 (t, J=6.9 Hz, 3H).
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N-(4-fluoro-3-(trifluoromethyl)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-495): A solution
of KMU-1-11 (140.8 mg, 0.480 mmol) and hydrazine hydrate (0.060 mL, 0.961 mmol, ~50% in
H2O) in 5.1 mL ethanol was stirred for one hour at room temperature. The solid was filtered and
dried under high vacuum to provide 90.6 mg (67.6%) of CDE-495 as a white solid. 1H NMR
(DMSO-d6, 400 MHz) δ 10.04 (bs, 1H), 9.36 (t, J=6 Hz, 1H), 7.64 (d, J=6.9 Hz, 1H), 7.59 (m,
1H), 7.42 (t, J=10.5 Hz, 1H), 4.50 (bs, 2H), 4.32 (d, J=6 Hz, 2H). 13C NMR (DMSO-d6, 100
MHz) δ 160.53, 158.35, 158.32 (d, J=252.7 Hz), 136.54 (d, J=2.9 Hz), 134.81 (d, J=8.6 Hz),
126.69 (d, J=3.8 Hz), 122.52 (q, J=269.8 Hz), 117.61 (d, J=21.0 Hz), 116.70 (dd, J=31.5 Hz,
J=12.4 Hz), 41.72; HRMS, DART calcd. for C10H9F4N3O2 [M+H+] 280.07090, found:
280.06799.

Ethyl 2-((4-isopropylbenzyl)amino)-2-oxoacetate (KMU-1-17): The procedure for the
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 4isopropylbenzylamine which gave 367.0 mg (80.7%) of KMU-1-17 as a pale white solid. 1H
NMR (CDCl3, 400 MHz) δ 7.32 (bs, 1H), 7.22 (m, 4H), 4.47 (d, J=6 Hz, 2H), 4.34 (q, J=7.3 Hz,
2H), 2.9 (sep, J=6.9 Hz, 1H), 1.38 (t, J=7.3 Hz, 3H), 1.23 (d, J=6.9 Hz, 6H).
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2-hydrazinyl-N-(4-isopropylbenzyl)-2-oxoacetamide (CDE-496): A solution of KMU-1-17
(160.1 mg, 0.642 mmol) and hydrazine hydrate (0.080 mL, 1.284 mmol, ~50% in H2O) in 6 mL
ethanol was stirred for one hour at room temperature with manual breakup of the solid required.
The solid was filtered and dried under high vacuum to provide 118.4 mg (78.7%) of CDE-496 as
a hard white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.00 (bs, 1H), 9.17 (t, J=6.4 Hz, 1H), 7.14
(s, 4H), 4.50 (bs, 2H), 4.24 (d, J=6.4 Hz, 2H), 2.81 (sep, J=7.3 Hz, 1H), 1.13 (d, J=6.9 Hz, 6H).
C NMR (DMSO-d6, 100 MHz) δ 160.26, 158.64, 147.58, 136.77, 127.94, 126.68, 42.44, 33.65,

13

24.46; HRMS, DART calcd. for C12H17N3O2 [M+H+] 236.13991, found: 236.13901.

Ethyl 2-((4-(dimethylamino)benzyl)amino)-2-oxoacetate (KMU-1-19): To a solution of 4(dimethylamino)benzylamine (0.270 mL, 1.83 mmol) and triethylamine (0.509 mL, 3.66 mmol)
in 2.05 mL of CH2Cl2 stirred in an ice bath, ethylchlorooxoacetate (0.21 mL, 1.92 mmol) was
added dropwise. The reaction was allowed to stir for one hour. The reaction mixture was then
diluted with 30 mL ethyl acetate and washed with 2 × 25 mL of 0.2N HCl, followed by 2 × 25
mL sat. aqueous NaHCO3. The organic phase was then dried with anhydrous MgSO4, filtered
and concentrated to provide 766.0 mg (quantitative yield) of KMU-1-19 as an impure solid. 1H
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NMR (CDCl3, 400 MHz) δ 7.29 (m, 1H), 6.66 (m, 4H), 4.4 (d, J=5.5 Hz, 2H), 4.24 (q, J=7.3
Hz, 2H), 2.94 (s, 6H), 1.36 (m, 3H).

N-(4-(dimethylamino)benzyl)-2-hydrazinyl-2-oxoacetamide (CDE-497): A solution of KMU1-19 (199.2 mg, 0.796 mmol) and hydrazine hydrate (0.099 mL, 1.592 mmol, ~50% in H2O) in 4
mL ethanol was stirred for one hour at room temperature. The solid was filtered and dried under
high vacuum to provide 37.5 mg (20.0%) of CDE-497 as a white solid. 1H NMR (DMSO-d6, 400
MHz) δ 9.97 (bs, 1H), 9.02 (t, J=6 Hz, 1H), 7.05 (d, J=8.3 Hz, 2H), 6.62 (d, J=8.7 Hz, 2H), 4.46
(bs, 2H), 4.15 (d, J=6.4 Hz, 2H), 2.81 (s, 6H). 13C NMR (DMSO-d6, 100 MHz) δ 160.01,
158.74, 150.16, 128.98, 126.89, 112.80, 42.23, 40.79; HRMS, DART calcd. for C11H16N4O2
[M+H+] 237.13514, found: 237.13499.

Ethyl 2-((4-ethylbenzyl)amino)-2-oxoacetate (KMU-1-22): The procedure for the synthesis of
KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 4- ethylbenzylamine
which gave 341.0 mg (79.4%) of KMU-1-22 as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ
7.32 (bs, 1H), 7.19 (q, J=8.2 Hz, 4H), 4.47 (d, J=6 Hz, 2H), 4.34 (q, J=6.9 Hz, 2H), 2.63 (q,
J=7.8 Hz, 2H), 1.38 (t, J=6.9 Hz, 3H), 1.22 (t, J=7.3 Hz, 3H).
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N-(4-ethylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-498): A solution of KMU-1-22 (138.5
mg, 0.589 mmol) and hydrazine hydrate (0.073 mL, 1.178 mmol, ~50% in H2O) in 4 mL ethanol
was stirred for one hour at room temperature. The solid was filtered and dried under high
vacuum to provide 100.8 mg (76.9%) of CDE-498 as an off-white solid. 1H NMR (DMSO-d6,
400 MHz) δ 9.99 (s, 1H), 9.16 (t, J=6.4 Hz, 1H), 7.12 (q, J=5 Hz, 4H), 4.49 (bs, 2H), 4.24 (d,
J=6.4 Hz, 2H), 2.52 (q, J=7.3 Hz, 2H), 1.12 (t, J=7.3 Hz, 3H). 13C NMR (DMSO-d6, 100 MHz)
δ 160.26, 158.64, 142.92, 136.62, 128.17, 127.94, 42.44, 28.34, 16.27; HRMS, DART calcd. for
C11H15N3O2 [M+H+] 222.12425, found: 222.12199.

Ethyl 2-((4-fluoro-3-methylbenzyl)amino)-2-oxoacetate (KMU-1-23): The procedure for the
synthesis of KMU-1-1 was followed, substituting 4-(difluoromethoxy)-benzylamine for 4fluoro-3-methylbenzylamine which gave 341.0 mg (79.4%) of KMU-1-22 as a yellow oil. 1H
NMR (CDCl3, 400 MHz) δ 7.34 (bs, 1H), 7.08 (m, 2H), 6.96 (t, J=9.2 Hz, 1H), 4.43 (d, J=6 Hz,
2H), 4.34 (q, J=7.4 Hz, 2H), 2.25 (d, J=1.8 Hz, 3H), 1.38 (t, J=7.3 Hz, 3H).

N-(4-fluoro-3-methylbenzyl)-2-hydrazinyl-2-oxoacetamide (CDE-499): A solution of KMU1-23 (186.9 mg, 0.782 mmol) and hydrazine hydrate (0.097 mL, 1.563 mmol, ~50% in H2O) in 4
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mL ethanol was stirred for one hour at room temperature. The solid was filtered and dried under
high vacuum to provide 149.6 mg (85.5%) of CDE-499 as a white solid. 1H NMR (DMSO-d6,
400 MHz) δ 10.00 (s, 1H), 9.2 (t, J=6 Hz, 1H), 7.05 (m, 3H), 4.49 (bs, 2H), 4.22 (d, J=6.4 Hz,
2H), 2.16 (s, 3H). 13C NMR (DMSO-d6, 100 MHz) δ 160.29, 160.20 (d, J=240.3 Hz), 158.57,
135.22 (d, J=3.8 Hz), 131.13 (d, J=5.7 Hz), 127.18 (d, J=7.6 Hz), 124.30 (d, J=17.2 Hz),
115.17 (d, J=22.9 Hz), 42.01, 14.67 (d, J=2.9 Hz); HRMS, DART calcd. for C10H12FN3O2
[M+H+] 226.09918, found: 226.09900.

Methyl 4-oxo-4-((3-(trifluoromethoxy)benzyl)amino)butanoate (CDE-501): To a solution of
3-(trifluoromethoxy)benzylamine (1.03 mL, 3.66 mmol) and pyridine (1.16 mL, 3.84 mmol) in
CH2Cl2 (20 mL) stirred in an ice bath, methyl-4-chloro-4-oxobutyrate (1.16 mL, 7.32 mmol) was
added dropwise. The reaction was allowed to react overnight, warming to room temperature. The
solution was then diluted with ethyl acetate and washed with 2 × 25 mL 0.2N HCl and 2 × 25
mL NaHCO3. The organic phase was dried with anhydrous MgSO4, filtered and dried under
vacuum to yield 1.7634 g (80.1%) of a viscous off-white material. 1H NMR (CDCl3, 400 MHz) δ
7.34 (t, J=8.7 Hz, 1H), 7.19 (d, J=7.4 Hz, 1H), 7.11 (bs, 2H), 6.10 (bs, 1H), 4.45 (d, J=6 Hz, 2H),
3.68 (m, 3H), 2.61 (tt, J=6.9 Hz, J=73.8 Hz, 4H). 13C NMR (CDCl3, 100 MHz) δ 173.57, 171.63,
149.53, 140.86, 130.07, 125.95, 120.50 (q, J=255.5 Hz), 120.09, 119.83, 51.92, 43.00, 30.99,
19.33; HRMS, DART calcd. for C13H14F3NO4 [M+H+] 306.09532, found: 306.09799.
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4-hydrazinyl-4-oxo-N-(3-(trifluoromethoxy)benzyl)butanamide (CDE-502): A solution of
CDE-501 (121.0 mg, 0.397 mmol) and hydrazine hydrate (0.247 mL, 3.970 mmol, ~50% in
H2O) in ethanol 3.90 mL was allowed to stir overnight. 2 drops of RO H2O was added and
product formation was verified via TLC (30:70 EtOAC:Hexanes). The solution was rotovapped
and dried under vacuum, giving yield to 92.4 mg (73.4%) of a white solid, CDE-502. 1H NMR
(DMSO-d6, 400 MHz) δ 8.93 (bs, 1H), 8.41 (t, J=5.5 Hz, 1H), 7.41 (m, 1H), 7.20 (m, 3H), 4.26
(d, J=6 Hz, 2H), 4.09 (bs, 2H), 2.37 (m, 2H), 2.24 (m, 2H). 13C NMR (DMSO-d6, 100 MHz) δ
172.00, 171.37, 148.96, 143.19, 130.41, 126.67, 120.77 (q, J=254.6 Hz), 119.99, 119.64, 41.97,
31.16, 29.37; HRMS, DART calcd. for C12H14F3N3O3 [M+H+] 306.10655, found: 306.10001.

4-oxo-4-((3-(trifluoromethoxy)benzyl)amino)butanoic acid (CDE-503): A solution of CDE501 (494.1 mg, 1.62 mmol) in 4 mL EtOH, 5 M NaOH (1.296 mL, 6.48 mmol) was added and
allowed to stir overnight. The reaction solution was diluted with 30 mL EtOAc, and washed with
2 × 25 mL 0.2 N HCl and 2 × 25 mL brine. The organic layer was dried with MgSO4, filtered
and the solvent was evaporated to yield 386.5 mg (82.0%) of CDE-503 as a brittle white solid.
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1

H NMR (DMSO-d6, 400 MHz) δ 12.05 (bs, 1h), 8.41 (t, J=5.9 Hz, 1H), 7.41 (m, 1H), 7.24 (d,

J=7.8 Hz, 1H), 7.19 (bs, 2H), 4.27 (d, J=6 Hz, 2H), 2.38 (m, 4H). 13C NMR (DMSO-d6, 100
MHz) δ 174.38, 171.79, 148.98, 143.21, 130.67, 126.63, 120.47 (q, J=254.6 Hz), 119.96, 119.63,
41.97, 30.45, 29.57; HRMS, DART calcd. for C12H12F3NO4 [M+H+] 292.07966, found:
292.08099.

N1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-N4-(3-(trifluoromethoxy)benzyl)succinamide (CDE504): To a solution of CDE-503 (95.6 mg, 0.328 mmol) in 6 mL CH2Cl2, 2-amino-1-pyrrolidin1-yl-ethanone hydrochloride (108.4 mg, 0.658 mmol), DMF (0.6 mL), HOBt · H2O (61.6 mg,
0.455 mmol), N-methylmorpholine (0.072 mL, 0.655 mmol) were added with stirring in an ice
bath, followed by the addition of EDC · HCl (75.7 mg, 0.395 mmol). The reaction mixture was
allowed to stir overnight. The stir bar was then removed and solvent was evaporated. A solution
of 4:1 EtOAc:hexanes (30 mL) was then added and transferred to a separatory funnel, leaving a
yellow oil behind. The organic layer was washed with 2 × 25 mL 0.1N NaOH and 2 × 25 mL
brine, dried with anhydrous MgSO4, filtered, and concentrated to give 67.9 mg (51.8%) of CDE504 as a white, granular solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.39 (t, J=6 Hz, 1H), 7.94 (t,
J=5.5 Hz, 1H), 7.39 (t, J=8.7 Hz, 1H), 7.24 (d, J=7.8 Hz, 1H), 7.19 (s, 2H), 4.26 (d, J=6 Hz, 2H),
3.79 (d, J=5.5 Hz, 2H), 3.34 (m, 2H), 3.25 (m, 2H), 2.38 (m, 4H), 1.78 (m, 4H). 13C NMR
(DMSO-d6, 100 MHz) δ 172.11, 171.99, 148.99, 143.22, 130.67, 126.66, 120.52 (q, J=254.6
Hz), 119.99, 119.61, 46.04, 45.44, 41.97, 41.79, 31.27, 31.02, 26.14, 24.22; HRMS, DART
calcd. for C18H22F3N3O4 [M+H+] 402.16408, found: 402.16199.
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N1-(2-morpholino-2-oxoethyl)-N4-(3-(trifluoromethoxy)benzyl)succinamide (CDE-505): To
a solution of CDE-503 (100.9 mg, 0.347 mmol) in 6.1 mL CH2Cl2, 2-amino-1-morpholino-1ethanone hydrochloride (125.1 mg, 0.693 mmol), DMF (0.5 mL), HOBt · H2O (58.8 mg, 0.435
mmol), N-methylmorpholine (0.076 mL, 0.691 mmol) were added with stirring in an ice bath,
followed by the addition of EDC · HCl (80.5 mg, 0.420 mmol). The reaction mixture was
allowed to stir overnight. The stir bar was then removed and solvent was evaporated. A solution
of 4:1 EtOAc:hexanes (30mL) was then added and transferred to a separatory funnel, leaving a
yellow oil behind. The organic layer was washed with 2 × 25 mL 0.1N NaOH and 2 × 25 mL
brine, dried with anhydrous MgSO4, filtered, and concentrated to give 62.2 mg (43.2%) of CDE505 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.39 (t, J=5.5 Hz, 1H), 7.95 (t, J=5 Hz,
1H), 7.41 (t, J=7.8 Hz, 1H), 7.24 (d, J=7.3 Hz, 1H), 7.19 (bs, 2H), 4.26 (d, J=6 Hz, 2H), 3.89 (d,
J=5.5 Hz, 2H), 3.51 (bs, 4H), 3.81 (bs, 4H). 13C NMR (DMSO-d6, 100 MHz) δ 172.09, 172.00,
167.78, 148.98, 143.22, 130.68, 126.66, 120.75 (q, J=254.6), 119.99, 119.63, 66.51 (d, J=6.7
Hz), 45.08, 40.65, 40.45, 31.21, 31.03; HRMS, DART calcd. for C18H22F3N3O5 [M+H+]
418.15898, found: 418.15302.

53

N1-(3-(trifluoromethoxy)benzyl)succinamide (CDE-506): 124.2 mg (0.407 mmol) of CDE501 was added to a reaction vial with a stir bar followed by the dropwise addition of ammonia in
methanol (4.0 mL, 181.0 mmol, 7 N). The solution was allowed to react overnight. TLC in 50:50
EtOAc:hexanes the next day showed that not all starting material had been consumed and
therefore more ammonia in methanol (2 mL, 90.0 mmol, 7 N) as well as ethanol (0.5 mL) was
added and allowed to react overnight. The solution was then rotovapped and the resulting solid
was triturated with chloroform to produce 44.0 mg (37.3%) of CDE-506 as a white, granular
solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.38 (t, J=5.9 Hz, 1H), 7.39 (m, 1H), 7.24 (d, J=7.8 Hz,
2H), 7.19 (s, 2H), 6.69 (s, 1H), 4.26 (d, J=6 Hz, 2H), 2.31 (m, 4H). 13C NMR (DMSO-d6, 100
MHz) δ 173.91, 172.25, 148.97, 143.27, 130.68, 126.64, 121.20 (q, J=254.6 Hz), 119.97, 119.62,
41.95, 31.04, 30.84; HRMS, DART calcd. for C12H13F3N2O3 [M+H+] 291.09565, found:
291.09601.

Methyl 3-oxo-3-((3-(trifluoromethoxy)benzyl)amino)propanoate (CDE-509): To a solution
of 3-trifluoromethoxy)benzylamine (1.03 mL, 7.22 mmol), pyridine (1.16 mL, 14.44 mmol), and
CH2Cl2 (20.5 mL) stirring in an ice bath, methyl malonyl chloride (0.812 mL, 7.58 mmol) was
added dropwise. The solution noticeably changed vibrant colors, from neon orange to yellow,
back to orange, upon the addition of methyl malonyl chloride. The reaction was allowed to stir,
warming to room temp, for 24 hours. The CH2Cl2 was then evaporated and the remainder diluted
with ethyl acetate (40 mL). The solution was then washed with 3 × 25 mL 0.2N HCl and 3 × 25
mL sat. NaHCO3, dried with anhydrous MgSO4, filtered and concentrated to provide 1.8915 g
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(90.0%) of crude material. Column chromatography was performed using a gradient of 20%,
40%, and 75% EtOAc:hexanes as the eluent to give 602.8 mg (28.7%) of CDE-509 as a powdery
white solid. TLC confirmed CDE-509 to have an r.f. of 0.4 in 75% EtOAc:hexanes. 1H NMR
(CDCl3, 400 MHz) δ 7.53 (bs, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 7.13 (s, 1H),
7.11 (bs, 1H), 4.5 (d, J=6 Hz, 2H), 3.74 (s, 3H), 3.38 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ
170.09, 165.03, 149.57, 140.41, 130.16, 125.98, 120.80 (q, J=255.5 Hz), 120.17, 119.95, 52.61
(m), 42.98, 40.79; HRMS, DART calcd. for C12H12F3NO4 [M+H+] 292.07966, found:
292.07599.

3-hydrazinyl-3-oxo-N-(3-(trifluoromethoxy)benzyl)propanamide (CDE-511): 73.5 mg
(0.253 mmol) of CDE-509 was dissolved in EtOH (2 mL) and hydrazine hydrate (0.128 mL,
1.012 mmol, ~50% in H2O) was added. The reaction was monitored by TLC and after 8 hours all
starting material had been consumed. The solution was rotovapped and concentrated to give 67.9
mg (92.3%) of CDE-511 as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.09 (bs, 1H), 8.52
(t, J=6 Hz, 1H), 7.42 (t, J=7.8 Hz, 1H), 7.29 (d, J=7.3 Hz, 1H), 7.23 (s, 1H), 7.21 (d, J=7.8 Hz,
1H), 4.29 (d, J=5.9 Hz, 2H), 4.22 (bs, 2H), 3.00 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ
167.35, 166.71, 148.99, 142.84, 130.70, 126.69, 120.40 (q, J=254.6 Hz), 120.06, 119.71, 42.28,
42.13; HRMS, DART calcd. for C11H12F3N3O3 [M+H+] 292.09089, found: 292.09201.
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(Z)-methyl 3-(3,4-dimethoxyphenyl)-2-((3-(trifluoromethoxy)benzyl)carbamoyl)acrylate
(CDE-512): CDE-509 (74.4 mg, 0.256 mmol), veratraldehyde (214.8 mg, 1.28 mmol), and
piperidine (0.006 mL, 0.064 mmol) were placed in a microwave tube and subjected to irradiation
for 7.5 minutes at 100 ºC at 250W. The solution was then diluted with EtOAc (30 mL) and
washed with 2 × 25 mL 0.1N HCl. The solution was then concentrated to give 265.2 mg (100%)
of crude material. The material was then subjected to column chromatography with 40%
EtOAc:hexanes as the eluent. 133.9 mg (100%) of crude material was recovered from the
column and triturated with hexanes to yield 30.8 mg (27.4%) of CDE-512 as a white crystalline
solid. 1H NMR (CDCl3, 400 MHz) δ 7.71 (s, 1H), 7.32 (t, J=7.8 Hz, 1H), 7.2 (d, J=7.8 Hz, 1H),
7.14 (bs, 3H), 7.11 (d, J=2.3 Hz, 1H), 6.8 (d, J=9.2 Hz, 1H), 6.19 (t, J=5.9 Hz, 1H), 4.59 (d,
J=6.4 Hz, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ 166.84,
165.66, 151.45, 149.57, 148.99, 143.00, 140.07, 130.11, 126.04, 125.76, 125.58, 124.60, 120.27
(q, J=256.5 Hz), 120.25, 119.99, 112.30, 110.96, 55.98, 55.87, 52.59, 43.08; HRMS, DART
calcd. for C21H20F3NO6 [M+H+] 440.13209, found: 440.12799.
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3-oxo-3-((3-(trifluoromethoxy)benzyl)amino)propanoic acid (CDE-521): CDE-509 (332.0
mg, 1.140 mmol) was dissolved in EtOH (6.90 mL) with stirring in an ice bath. 5M NaOH (0.92
mL, 4.562 mmol) was added dropwise and the reaction was allowed to proceed overnight at
room temperature. The solution was diluted with chilled 30 mL CH2Cl2 and washed 2 × 25 mL
chilled 0.2N HCl and 2 × 25 mL chilled brine. The organic layers were then dried with
anhydrous MgSO4, filtered and concentrated via rotovap at low heat to give 197.0 mg (62.3%) of
CDE-521 as an off-white brittle solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.61 (t, J=6 Hz, 1H),
7.42 (t, J=7.8 Hz, 1H), 7.27 (m, 2H), 7.23 (d, J=6 Hz, 1H), 4.31 (d, J=6 Hz, 2H), 3.18 (s, 2H).
C NMR (DMSO-d6, 100 MHz) δ 170.04, 166.53, 149.02, 142.76, 130.70, 126.67, 120.61 (q, J=
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254 Hz), 120.00, 119.77, 43.19, 42.06; HRMS, DART calcd. for C11H10F3NO4 [M+H+]
278.06401, found: 278.06601.

N1-(2-oxo-2-(pyrrolidin-1-yl)ethyl)-N3-(3-(trifluoromethoxy)benzyl)malonamide (CDE522): To a solution of CDE-521 (68.5 mg, 0.250 mmol) in 7.5 mL CH2Cl2, 2-amino-1pyrrolidin-1-yl-ethanone hydrochloride (85.7 mg, 0.500 mmol), DMF (0.51 mL), HOBt · H2O
(49.0 mg, 0.300 mmol), N-methylmorpholine (0.0550 mL, 0.500 mmol) were added with stirring
in an ice bath, followed by the addition of EDC · HCl (53.8 mg, 0.300 mmol). The reaction
mixture was allowed to stir overnight. The stir bar was then removed and solvent was
evaporated. A solution of 4:1 EtOAc:hexanes (30 mL) was then added and transferred to a
separatory funnel, leaving a yellow viscous material behind. The organic layer was washed with
2 × 25 mL 0.2N NaOH and 2 × 25 mL brine, dried with anhydrous MgSO4, filtered, and
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concentrated. The off-white crystalline solid was then triturated with hexanes to give 31.9 mg
(33.2%) of CDE-522 as a white powdery solid. 1H NMR (CDCl3, 400 MHz) δ 7.86 (bs, 1H),
7.34 (t, J=7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 7.10 (m, 3H), 4.47 (d, J=6 Hz, 2H), 3.97 (d, J=4.1
Hz, 2H), 3.49 (t, J=6.9 Hz, 2H), 3.37 (t, J=6.4 Hz, 2H), 3.31 (s, 2H), 1.93 (m, 4H). 13C NMR
(CDCl3, 100 MHz) δ 168.12, 166.46, 165.93, 149.50, 140.67, 130.06, 126.03, 120.51 (q, J=255
Hz), 120.21, 119.76, 46.19, 45.60, 26.00, 24.20; HRMS, DART calcd. for C17H20F3N3O4
[M+H+] 388.14842, found: 388.14401.

N1-(2-morpholino-2-oxoethyl)-N3-(3-(trifluoromethoxy)benzyl)malonamide (CDE-523):
To a solution of CDE-521 (82.0 mg, 0.300 mmol) in 6.0 mL CH2Cl2, 2-amino-1-morpholino-1ethanone hydrochloride (109.2 mg, 0.600 mmol), DMF (0.50 mL), HOBt · H2O (55.3 mg, 0.360
mmol), N-methylmorpholine (0.0660 mL, 0.600 mmol) were added with stirring in an ice bath,
followed by the addition of EDC · HCl (68.7 mg, 0.360 mmol). The reaction mixture was
allowed to stir overnight. The stir bar was then removed and solvent was evaporated. A solution
of 4:1 EtOAc:hexanes (30 mL) was then added and transferred to a separatory funnel, leaving a
yellow viscous material behind. The organic layer was washed with 2 × 25 mL 0.2N NaOH and
2 × 25 mL brine, dried with anhydrous MgSO4, filtered, and concentrated. The white solid was
then triturated with hexanes to give 57.1 mg (47.2%) of CDE-523 as a white solid. 1H NMR
(CDCl3, 400 MHz) δ 7.63 (bs, 1H), 7.34 (t, J=7.4 Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 7.17 (bs, 1H),
7.12 (bs, 1H), 7.10 (bs, 1H), 4.49 (d, J=6 Hz, 2H), 4.05 (d, J=4.1 Hz, 2H), 3.67 (m, 6H), 3.39 (t,
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J=5.0 Hz, 2H), 3.30 (s, 2H) 13C NMR (CDCl3, 100 MHz) δ 167.94, 166.51, 166.24, 149.50,
140.47, 130.09, 126.03, 120.50 (q, J=255 Hz), 120.17, 119.82, 66.67, 66.35, 44.93, 42.93, 42.75,
42.42, 41.30; HRMS, DART calcd. for C17H20F3N3O5 [M+H+] 404.14332, found: 404.14099.

N1-(3-(trifluoromethoxy)benzyl)malonamide (CDE-524): CDE-509 (71.4 mg, 0.245 mmol)
was dissolved in ammonia in methanol (28.1 mL, 1273 mmol, 7 N) in an ice bath and stirred for
3.5 hours. The vial was then moved to cold storage for an additional 9 hours at which time the
solution was tested via TLC using 1:1 EtOAc:hexanes to verify all starting material had been
consumed and no side products were produced. The solvent was evaporated and the solution
concentrated to give 52.0 mg (77.6%) of CDE-524 as a green-tinted tacky solid. 1H NMR
(CDCl3, 400 MHz) δ 7.63 (bs, 1H), 7.32 (t, J=8.2 Hz, 1H), 7.25 (s, 1H), 7.17 (d, J=7.8 Hz, 1H),
7.11 (s, 1H), 7.00 (bs, 1H), 5.80 (bs, 1H), 4.43 (d, J=17 Hz, 2H), 3.24 (s, 2H). 13C NMR
(CDCl3, 100 MHz) δ 169.88, 167.27, 149.55, 140.26, 130.16, 125.89, 120.51 (q, J=255 Hz),
120.11, 119.96, 43.03, 42.68; HRMS, DART calcd. for C11H11F3N2O3 [M+H+] 277.08000,
found: 277.07901.
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